An announcement from Innate Pharma SA ( (FR:IPH) ) is now available.
Innate Pharma announced that its novel Antibody Drug Conjugate (ADC) IPH4502, which targets Nectin-4, has been selected for presentation at the AACR 2025 Annual Meeting in Chicago. This ADC, currently in Phase 1 trials, has shown promising preclinical anti-tumor efficacy, particularly in models resistant to existing treatments, indicating its potential to extend beyond urothelial carcinoma. The selection of IPH4502 for the AACR meeting underscores Innate Pharma’s innovative approach in cancer therapeutics and could enhance its positioning in the oncology sector.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical giants like Sanofi and AstraZeneca to drive innovation and research, with its headquarters in Marseille, France, and a US office in Rockville, MD.
Technical Sentiment Signal: Hold
Current Market Cap: $166.7M
Learn more about IPH stock on TipRanks’ Stock Analysis page.